Literature DB >> 2579439

Diagnosis and treatment of malignant pleural effusion.

F H Hausheer, J W Yarbro.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579439

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  28 in total

1.  BTS guidelines for the management of malignant pleural effusions.

Authors:  G Antunes; E Neville; J Duffy; N Ali
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  Intrapleural mitoxantrone for the palliative treatment of malignant pleural effusions.

Authors:  M Morales; M C Expósito
Journal:  Support Care Cancer       Date:  1995-03       Impact factor: 3.603

3.  Inhibition of pleural metastasis of collecting duct carcinoma of the kidney by modified cytokine-induced killer cells: A case report and review of the literature.

Authors:  Jingyi Liu; Jun Sui; Zhiwei Zhang; Xiubao Ren; Li Luan; Qisheng Yang; Songhai Gu; Rudolf Wank; Barbara Laumbacher; Xin Song
Journal:  Oncol Lett       Date:  2010-09-08       Impact factor: 2.967

Review 4.  Management of malignant pleural effusions.

Authors:  M H Tattersall; M J Boyer
Journal:  Thorax       Date:  1990-02       Impact factor: 9.139

5.  Palliative iodized talc pleurodesis with instillation via tube thoracostomy.

Authors:  A Türler; M Gawenda; M Walter
Journal:  Support Care Cancer       Date:  1997-01       Impact factor: 3.603

Review 6.  Management of malignant pleural effusions.

Authors:  F Grossi; M C Pennucci; L Tixi; M A Cafferata; A Ardizzoni
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

7.  Ezrin and BCAR1/p130Cas mediate breast cancer growth as 3-D spheroids.

Authors:  Sophya Konstantinovsky; Ben Davidson; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2012-04-04       Impact factor: 5.150

8.  Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells.

Authors:  S Yano; H Shinohara; R S Herbst; H Kuniyasu; C D Bucana; L M Ellis; I J Fidler
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

9.  Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions.

Authors:  Ben Davidson; Tian-Li Wang; Ie-Ming Shih; Aasmund Berner
Journal:  Hum Pathol       Date:  2008-03-04       Impact factor: 3.466

10.  Breast carcinoma cells in primary tumors and effusions have different gene array profiles.

Authors:  Sophya Konstantinovsky; Yoav Smith; Sofia Zilber; Helene Tuft Stavnes; Anne-Marie Becker; Jahn M Nesland; Reuven Reich; Ben Davidson
Journal:  J Oncol       Date:  2009-08-11       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.